When we got started at FierceBiotech more than 13 years ago, our world was actually quite small. The U.S. biotech hubs consumed a lot of our attention, along with the pipelines of all the Big Pharma companies, wherever they were based. But 6 years ago, well after Europe found Fierce, we began to seriously concentrate some added efforts on the continent. The EuroBiotech Report followed, and now we're stepping halfway around the world to focus on Asia with our new, twice-weekly report, FiercePharmaAsia.
Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.
Japan's Takeda Pharmaceutical opened an emerging markets and vaccines headquarters in the gleaming new research hub Biopolis on Feb. 25 in the wealthy city-state as it looks to bring a Phase III dengue candidate through trials successfully and challenge Sanofi's lead in the space.
The clinical side of orphan drug use has many twists and turns, not least of which is matching patient ability to pay with the right drug and an openness to understand the dynamics of a "Dallas Buyers Club" approach to use.
A research team at the National University of Singapore has published a paper on a novel strategy to prevent progression of inflammation-associated cancers.
A team of scientists from Singapore's Nanyang Technological University and the Singapore Eye Research Institute is developing an injectable eye medication that utilizes extended-release nanoparticles to treat glaucoma, or fluid buildup in the eye that can lead to blindness.
SINGAPORE-- Nanyang Technological University (NTU) researchers in Singapore working with colleagues at other local institutions have developed an antibody with the potential to help patients suffering from pneumonia and influenza to recover faster, NTU said in a news release.
SINGAPORE-- Singapore plans to offer a version of universal healthcare that builds on catastrophic insurance mandatory under the country's Central Provident fund.
Japanese drugmaker Chugai Pharmaceutical is planning a major expansion of its Singapore research outpost, laying out 476 million Singapore dollars ($374 million) over 7 years as it hits the gas on antibody research.
The National Cancer Centre Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration and Singapore's Health Sciences Authority, highlighting the wealthy city-state's push to be a leader in early stage clinical trials in Asia.